Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00697151 · ClinicalTrials.gov registry record · Phase 4

Patent Foramen Ovale in Cryptogenic Stroke Study

A Phase 4 study of Ischemic Stroke and Patent Foramen Ovale, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
630
Enrollment target
1
Study location

NCT00697151 is a Phase 4 study of Ischemic Stroke and Patent Foramen Ovale that has completed, run by Columbia University. The registered enrollment target is 630 participants, below the 1,454-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00697151, a Phase 4 study of Ischemic Stroke and Patent Foramen Ovale, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
630 participants
Enrollment target
1
Study location

Study Summary

The study sought to assess the rate of recurrent stroke and death in stroke patients with a patent foramen ovale randomized to treatment with warfarin or aspirin. This was a multicenter study conducted at 48 U.S. Institutions.

Interventions

  • DRUG Aspirin
  • DRUG Warfarin

Study Locations (1)

New York

  • Columbia College of Physicians and Surgeons - New York

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 1993-06
Est. Completion 2000-06
Phase Phase 4

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT00697151

The ClinicalTrials.gov registry entry for NCT00697151 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,454-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (57% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.

NCT00697151 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00697151 about?

NCT00697151 is a clinical study titled "Patent Foramen Ovale in Cryptogenic Stroke Study". The study sought to assess the rate of recurrent stroke and death in stroke patients with a patent foramen ovale randomized to treatment with warfarin or aspirin. This was a multicenter study conducted at 48 U.S. Institutions.

What is the current status of trial NCT00697151?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 630 participants. The study started on 1993-06. Estimated completion is 2000-06.

What conditions does trial NCT00697151 study?

This clinical trial studies the following conditions: Ischemic Stroke, Patent Foramen Ovale.

What interventions are being tested in trial NCT00697151?

The interventions under investigation include: Aspirin (DRUG), Warfarin (DRUG).

Who is sponsoring clinical trial NCT00697151?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00697151 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.